(Reuters) - Supernus Pharmaceuticals Inc said the U.S. health regulator granted a tentative approval to its epilepsy treatment Trokendi XR, sending its shares up 38 percent before the bell. The company said the U.S. Food and Drug Administration completed a review of Trokendi, an extended release version of Johnson & Johnson's widely-used epilepsy drug Topamax, and did not seek any additional ...

Read the original article
Brought to you by Yahoo! News

Return to Epilepsy News